{"commentary":{"count":26,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":18,"youtube":5,"podcast":2,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03656536\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"FIGHT-302","nct_id":"NCT03656536","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fight-302-nct03656536. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"FIGHT-302","arms":[{"description":null,"label":"Pemigatinib","type":"EXPERIMENTAL"},{"description":"Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.","label":"Gemcitabine + Cisplatin","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-07-07","type":"ACTUAL"},"conditions":["Unresectable Cholangiocarcinoma","Metastatic Cholangiocarcinoma"],"enrollment":{"count":167,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pemigatinib","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"}],"last_update":"2026-08-11","lead_sponsor":"Incyte Corporation","official_title":"A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Randomized Treatment Period: Progression-free Survival (PFS)","timeFrame":"up to 1422 days"},{"measure":"Randomized Treatment Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time","timeFrame":"up to 1422 days"},{"measure":"Transition Period: PFS","timeFrame":"up to 1496 days"},{"measure":"Transition Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time","timeFrame":"up to 1496 days"}],"references":[{"citation":"Bekaii-Saab TS, Melisi D, Wilmink H, Garufi C, Tran N, Tortora G, De Braud F, Frodin JE, Lonardi S, Lin E, Babiker H, Lin B, Fornaro L, Munoz Martin A, Bridgewater J, Knox JJ, De Vos-Geelen J, Scott-Brown M, Veronese L, Ioannidis S, Gilmartin A, Janik JE, Guo Y, Furuse J, Ioka T, Rimassa L, Vogel A. Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial. J Clin Oncol. 2026 Jun 1:JCO2600788. doi: 10.1200/JCO-26-00788. Online ahead of print.","pmid":"42223137","type":"DERIVED"},{"citation":"Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Feliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020 Oct;16(30):2385-2399. doi: 10.2217/fon-2020-0429. Epub 2020 Jul 17.","pmid":"32677452","type":"DERIVED"}],"start_date":{"date":"2019-06-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma","url":"https://clinicaltrials.gov/study/NCT03656536"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fight-302-nct03656536"}